Simultaneous Quantification of Amorphous and Crystalline Valsartan in Tablets Using Raman Spectroscopy and Chemometrics Tools

AUTOR(ES)
FONTE

Journal of the Brazilian Chemical Society

DATA DE PUBLICAÇÃO

2022

RESUMO

Valsartan is an antihypertensive active pharmaceutical ingredient (API), it is used in the amorphous state in the commercial products. As amorphous materials are metastable, amorphous valsartan can crystallize to valsartan E, promoting changes in the dissolution and bioavailability of the drug. Tablets containing metastable forms of APIs need special conditions for transport and storage in order to avoid crystallization (from amorphous state) or polymorphic transitions (from less stable crystalline structures). A multivariate calibration model based on interval partial least squares (iPLS) regression allied to net analyte signal (NAS) algorithm was built to simultaneously quantify amorphous (VAL-AM) and crystalline (VAL-E) valsartan. Mixtures of VAL-AM and VAL-E were used to produce tablets in order to simulate the crystallization of VAL-AM in a range from 0 to 100% of conversion. The calibration set included 11 samples and 5 samples were used as the external validation set. The following parameters of merit (POM) were obtained for both polymorphs in order to evaluate the calibration model quality: root mean square error (RMSE) for cross validation (RMSECV), validation (RMSEV) and calibration (RMSEC), sensitivity (SEN), selectivity (SEL), analytical sensitivity (γ), inverse analytical sensitivity (γ−1), limit of detection (LOD) and limit of quantification (LOQ).

Documentos Relacionados